|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MCTP2 |
Gene summary for MCTP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MCTP2 | Gene ID | 55784 |
| Gene name | multiple C2 and transmembrane domain containing 2 | |
| Gene Alias | MCTP2 | |
| Cytomap | 15q26.2 | |
| Gene Type | protein-coding | GO ID | GO:0001505 | UniProtAcc | Q6DN12 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55784 | MCTP2 | CA_HPV_1 | Human | Cervix | CC | 1.16e-02 | -7.50e-02 | 0.0264 |
| 55784 | MCTP2 | CCI_2 | Human | Cervix | CC | 4.72e-07 | 1.12e+00 | 0.5249 |
| 55784 | MCTP2 | CCI_3 | Human | Cervix | CC | 7.83e-04 | 4.99e-01 | 0.516 |
| 55784 | MCTP2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.15e-30 | -8.01e-01 | 0.0155 |
| 55784 | MCTP2 | HTA11_2951_2000001011 | Human | Colorectum | AD | 5.41e-06 | -9.18e-01 | 0.0216 |
| 55784 | MCTP2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.46e-15 | 6.51e-01 | -0.1954 |
| 55784 | MCTP2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.75e-02 | -4.59e-01 | -0.1207 |
| 55784 | MCTP2 | HTA11_866_3004761011 | Human | Colorectum | AD | 8.33e-14 | -6.56e-01 | 0.096 |
| 55784 | MCTP2 | HTA11_9408_2000001011 | Human | Colorectum | AD | 4.53e-05 | -9.15e-01 | 0.0451 |
| 55784 | MCTP2 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.30e-06 | -6.93e-01 | 0.0528 |
| 55784 | MCTP2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 2.55e-11 | -6.15e-01 | 0.0338 |
| 55784 | MCTP2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.03e-08 | -5.23e-01 | 0.0674 |
| 55784 | MCTP2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 5.15e-03 | -3.77e-01 | 0.0588 |
| 55784 | MCTP2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.23e-06 | -3.81e-01 | 0.294 |
| 55784 | MCTP2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.54e-43 | -8.92e-01 | 0.3859 |
| 55784 | MCTP2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.04e-05 | -7.59e-01 | 0.2585 |
| 55784 | MCTP2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.20e-55 | -1.01e+00 | 0.3005 |
| 55784 | MCTP2 | F007 | Human | Colorectum | FAP | 1.30e-03 | -4.12e-01 | 0.1176 |
| 55784 | MCTP2 | A001-C-207 | Human | Colorectum | FAP | 9.79e-08 | -4.97e-01 | 0.1278 |
| 55784 | MCTP2 | A015-C-203 | Human | Colorectum | FAP | 1.38e-48 | -9.17e-01 | -0.1294 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | CRC |  |
| Stomach | GC |  |
| Stomach | CAG with IM |  |
| Stomach | CSG |  |
| Stomach | CAG |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0023061 | Colorectum | FAP | signal release | 94/2622 | 463/18723 | 1.06e-04 | 1.76e-03 | 94 |
| GO:0050804 | Colorectum | CRC | modulation of chemical synaptic transmission | 70/2078 | 439/18723 | 1.15e-03 | 1.33e-02 | 70 |
| GO:0099177 | Colorectum | CRC | regulation of trans-synaptic signaling | 70/2078 | 440/18723 | 1.23e-03 | 1.38e-02 | 70 |
| GO:00230611 | Colorectum | CRC | signal release | 72/2078 | 463/18723 | 1.95e-03 | 1.96e-02 | 72 |
| GO:0019932 | Lung | AIS | second-messenger-mediated signaling | 46/1849 | 312/18723 | 3.79e-03 | 3.52e-02 | 46 |
| GO:00199321 | Lung | MIAC | second-messenger-mediated signaling | 30/967 | 312/18723 | 8.15e-04 | 1.80e-02 | 30 |
| GO:0051588 | Lung | MIAC | regulation of neurotransmitter transport | 13/967 | 100/18723 | 1.89e-03 | 3.02e-02 | 13 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| MCTP2 | MMC | Lung | Healthy | ID1,BCAS2,THBS1, etc. | 2.09e-03 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MCTP2 | SNV | Missense_Mutation | c.678N>C | p.Lys226Asn | p.K226N | Q6DN12 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| MCTP2 | SNV | Missense_Mutation | c.2075N>C | p.Ile692Thr | p.I692T | Q6DN12 | protein_coding | tolerated(0.26) | benign(0.006) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| MCTP2 | SNV | Missense_Mutation | novel | c.2185N>T | p.Val729Phe | p.V729F | Q6DN12 | protein_coding | tolerated(0.16) | benign(0.424) | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| MCTP2 | SNV | Missense_Mutation | novel | c.1968C>G | p.Ile656Met | p.I656M | Q6DN12 | protein_coding | tolerated(0.08) | possibly_damaging(0.856) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| MCTP2 | SNV | Missense_Mutation | c.714N>C | p.Leu238Phe | p.L238F | Q6DN12 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MCTP2 | SNV | Missense_Mutation | c.162N>A | p.Asp54Glu | p.D54E | Q6DN12 | protein_coding | deleterious(0) | benign(0.371) | TCGA-BH-A0DX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| MCTP2 | SNV | Missense_Mutation | c.338N>A | p.Leu113His | p.L113H | Q6DN12 | protein_coding | tolerated(0.22) | benign(0) | TCGA-D8-A1JP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| MCTP2 | SNV | Missense_Mutation | novel | c.2207N>G | p.Gln736Arg | p.Q736R | Q6DN12 | protein_coding | tolerated(0.49) | benign(0.013) | TCGA-OL-A66J-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MCTP2 | insertion | Frame_Shift_Ins | novel | c.1788_1788+1insCCTGGGACTCCTTGGCCATTTGTTG | p.Ile597ProfsTer10 | p.I597Pfs*10 | Q6DN12 | protein_coding | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| MCTP2 | insertion | Frame_Shift_Ins | novel | c.1412_1413insG | p.Val473GlyfsTer5 | p.V473Gfs*5 | Q6DN12 | protein_coding | TCGA-AC-A6NO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |